deferasiroks pharmascience 90 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - deferasiroks - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 90 mg deferasiroksa
tikagrelor pharmascience 60 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - tikagrelor - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 60 mg tikagrelora
tikagrelor pharmascience 90 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - tikagrelor - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 90 mg tikagrelora
bosentan pharmascience 62,5 mg/1 tableta film tableta
evropa lijek pharma d.o.o. - Бозентан - film tableta - 62,5 mg/1 tableta - jedna film tableta sadrži: 62,5 mg bosentana (u obliku bosentan monohidrata)
bosentan pharmascience 125 mg/1 tableta film tableta
evropa lijek pharma d.o.o. - Бозентан - film tableta - 125 mg/1 tableta - jedna film tableta sadrži: 125 mg bosentana (u obliku bosentan monohidrata)
bosentan pharmascience 62.5mg film tableta
"evropa lek pharma" doo podgorica - bosentan - film tableta - 62.5mg
bosentan pharmascience 125mg film tableta
"evropa lek pharma" doo podgorica - bosentan - film tableta - 125mg
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
abirateron pharmascience 500 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 500 mg abirateronacetata
erlotinib pharmascience 100mg film tableta
"evropa lek pharma" doo podgorica - erlotinib - film tableta - 100mg